Hematologic malignacy
Conditions
Interventions
Hematopoietic stem cell transplantation group:No
Sponsors
The First Affiliated Hospital of Zhejiang University School of Medicine
Eligibility
Sex/Gender
Male
Age
15 Years to 67 Years
Inclusion criteria
Inclusion criteria: 1. The subjects or their legal representatives signed the informed consent before the clinical study; 2. Women of childbearing age were negative in pregnancy test within 14 days before the administration of the test drug; 3. Subjects aged 15-67 years; 4. Patients with malignant hematological diseases received peripheral blood stem cell donor source T cell replete haoloidentical stem cell transplantation; 5. Subjects with ECOG score of 0-2; 6. Subjects without major organ dysfunction.
Exclusion criteria
Exclusion criteria: 1. Patients with severe liver and kidney function (alanine aminotransferase > 2.5 x ULN, serum creatinine > 1.5 x ULN), cardiopulmonary dysfunction (cardiac function NYHA III/IV, cardiac ejection fraction 2; 5. Patients with secondary tumor; 6. Patients who cannot independently choose to enter or exit clinical trials due to serious central nervous system disease or mental disease.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival;Non-relapse mortality;Cumulative incidence of graft versus host disease;Disease free survival;Cumulative incidence of relapse; | — |
Countries
China
Contacts
Public ContactHuang he
The First Affiliated Hospital of Zhejiang University School of Medicine
Outcome results
None listed